Mark Nelson, MD
Ophthalmology · Tacoma, WANPI 1689647109
Payments from drug & device makers
Across 41 payments — averaging $173.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Carl Zeiss Meditec USA, Inc.$2K
- AbbVie$397
- Regeneron Healthcare Solutions, Inc.$283
- Alimera Sciences, Inc.$233
- Genentech USA, Inc.$212
- plus $680 from 7 others
What the payments were for
- Consulting fees$3,45048%
- Food & beverage$1,55622%
- Other$2,12030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $3,200 |
| Carl Zeiss Meditec USA, Inc. | 1 | $2,120 |
| AbbVie(2 entities) | 7 | $397 |
| Regeneron Healthcare Solutions, Inc. | 7 | $283 |
| Alimera Sciences, Inc. | 4 | $233 |
| Genentech USA, Inc. | 6 | $212 |
| Dutch Ophthalmic, USA | 2 | $147 |
| Astellas Pharma US Inc | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $94 |
| Apellis Pharmaceuticals, Inc. | 1 | $87 |
| Eyepoint US, Inc. | 4 | $82 |
| Alcon | 2 | $79 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $67 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEOVU$3,200
- LUMERA 700$2,120
- Venclexta$250
- SUSVIMO$123
- EVA, combined machine$122
- TISSUEBLUE$122
- EYLEA$115
- Iluvien$114
How this compares
$7,125 in reported general payments places this provider in the 85th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 119 | $3,968 |
| Brimonidine Tartrate | 41 | $701 |
| Ciprofloxacin Hcl | 69 | $674 |
| Latanoprost | 27 | $163 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $153 |
| Timolol Maleate | 13 | $110 |
| Ofloxacin | 13 | $107 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Tacoma
- Niraj PatelTacoma$63K
- Andrew KopsteinTacoma$57K
- Clifton PerryTacoma$50K
- Joseph PhamTacoma$10K
- Victor ChiuTacoma$10K
- Jacob LightTacoma$10K
- Robert WirthlinSpokane$2.4M
- Laura PerimanSeattle$1.9M
- Todd SchneidermanSilverdale$602K
- Sheldon CowenSeattle$560K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.